These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 32119654)
21. Meta-analysis for bioequivalence studies: interchangeability of generic drugs and similar containing Hydrochlorothiazide is possible but not with Enalapril Maleate. Lopes RA; Neves Fde A J Bras Nefrol; 2010; 32(2):173-81. PubMed ID: 21103677 [TBL] [Abstract][Full Text] [Related]
22. Frequency estimator for assessing of follow-on biologics. Lu Y; Zhang ZZ; Chow SC J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640 [TBL] [Abstract][Full Text] [Related]
23. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines. Martínez-López de Castro N; Matilla-Fernández MB; Fraga-Fuentes MD; Mangues-Bafalluy I; Asensi-Díez R; Cajaraville-Ordoñana G Farm Hosp; 2018 Jul; 42(4):180-183. PubMed ID: 29959844 [TBL] [Abstract][Full Text] [Related]
24. Quantitative assessment of the switchability of generic products. Karalis V; Bialer M; Macheras P Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332 [TBL] [Abstract][Full Text] [Related]
25. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592 [TBL] [Abstract][Full Text] [Related]
26. Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting. Lamarque V; Merle L; Demarez JP; Therapie; 2008; 63(4):301-9. PubMed ID: 18937910 [TBL] [Abstract][Full Text] [Related]
27. Scientific factors and current issues in biosimilar studies. Chow SC; Endrenyi L; Lachenbruch PA; Mentré F J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559 [TBL] [Abstract][Full Text] [Related]
28. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Bialer M; Midha KK Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761 [TBL] [Abstract][Full Text] [Related]
29. Generic clozapine: a cost-saving alternative to brand name clozapine? Tse G; Thompson D; Procyshyn RM Pharmacoeconomics; 2003; 21(1):1-11. PubMed ID: 12484800 [TBL] [Abstract][Full Text] [Related]
30. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system. Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406 [TBL] [Abstract][Full Text] [Related]
31. International harmonization of bioequivalence studies and issues shared in common. Nakai K; Fujita M; Ogata H Yakugaku Zasshi; 2000 Nov; 120(11):1193-200. PubMed ID: 11190204 [TBL] [Abstract][Full Text] [Related]
32. [Bioequivalence and generics of index drugs with narrow therapeutic margins]. Le Corre P Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591 [TBL] [Abstract][Full Text] [Related]
33. Nonbioequivalent prescription drug interchangeability, concerns on patient safety and drug market dynamics in Brazil. Paumgartten FJR; Oliveira ACAX Cien Saude Colet; 2017 Aug; 22(8):2549-2558. PubMed ID: 28793071 [TBL] [Abstract][Full Text] [Related]
34. Opportunities and Challenges Related to the Implementation of Model-Based Bioequivalence Criteria. Seng Yue C; Ozdin D; Selber-Hnatiw S; Ducharme MP Clin Pharmacol Ther; 2019 Feb; 105(2):350-362. PubMed ID: 30375647 [TBL] [Abstract][Full Text] [Related]
35. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Borgheini G Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486 [TBL] [Abstract][Full Text] [Related]
37. Biosimilar medical products - licensing, pharmacovigilance and interchangeability. Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414 [TBL] [Abstract][Full Text] [Related]
38. The similarity question for biologicals and non-biological complex drugs. Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826 [TBL] [Abstract][Full Text] [Related]
39. The US approach to biosimilars: the long-awaited FDA approval pathway. Calvo B; Zuñiga L BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677 [TBL] [Abstract][Full Text] [Related]